Biocon stock declines after FDA inspection issues
after close1 source ↓written by the desknot a recommendation
- Biocon's stock fell
- 1%
- following the US
- 30 Apr 2026
Biocon's stock fell 1% on 30 Apr 2026 following the US FDA's identification of five issues at its Bengaluru biosimilars facility during an inspection. The company maintains these are procedural and poses no risk to data integrity. Notably, Biocon secured Health Canada approvals for two denosumab biosimilars, indicating ongoing progress in the global market.
Not investment advice. For informational purposes only.